TransMedics Group, Inc. (NASDAQ:TMDX) Receives $144.25 Average Target Price from Brokerages

TransMedics Group, Inc. (NASDAQ:TMDX) has earned a consensus recommendation of “Moderate Buy” from the ten brokerages that are covering the stock, Marketbeat reports. Four research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $144.25.

Several brokerages have commented on TMDX. Canaccord Genuity Group raised their price objective on shares of TransMedics Group from $147.00 to $148.00 and gave the stock a “buy” rating in a report on Wednesday, December 17th. Evercore ISI began coverage on TransMedics Group in a research note on Tuesday, September 16th. They issued an “outperform” rating and a $155.00 target price for the company. Needham & Company LLC lifted their price target on TransMedics Group from $148.00 to $166.00 and gave the company a “buy” rating in a research report on Monday, December 8th. Wall Street Zen raised TransMedics Group from a “hold” rating to a “buy” rating in a research note on Sunday, December 28th. Finally, Jefferies Financial Group began coverage on TransMedics Group in a research report on Monday, October 13th. They set a “buy” rating and a $145.00 price objective for the company.

TransMedics Group Stock Performance

NASDAQ:TMDX opened at $126.28 on Friday. The company has a quick ratio of 7.13, a current ratio of 7.69 and a debt-to-equity ratio of 1.43. The firm’s fifty day simple moving average is $128.79 and its 200 day simple moving average is $121.95. The stock has a market cap of $4.31 billion, a P/E ratio of 51.13 and a beta of 2.03. TransMedics Group has a twelve month low of $55.00 and a twelve month high of $156.00.

TransMedics Group (NASDAQ:TMDX) last posted its earnings results on Wednesday, October 29th. The company reported $0.66 EPS for the quarter, topping the consensus estimate of $0.37 by $0.29. The firm had revenue of $143.82 million during the quarter, compared to analysts’ expectations of $145.33 million. TransMedics Group had a net margin of 16.20% and a return on equity of 31.42%. The company’s quarterly revenue was up 32.2% compared to the same quarter last year. During the same period last year, the company posted $0.12 EPS. As a group, research analysts predict that TransMedics Group will post 1 EPS for the current year.

Insider Buying and Selling at TransMedics Group

In related news, Director David Weill sold 5,000 shares of the business’s stock in a transaction dated Wednesday, December 3rd. The shares were sold at an average price of $138.64, for a total transaction of $693,200.00. Following the sale, the director owned 12,134 shares of the company’s stock, valued at $1,682,257.76. The trade was a 29.18% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Anil P. Ranganath sold 3,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 25th. The shares were sold at an average price of $145.22, for a total transaction of $435,660.00. Following the transaction, the insider directly owned 13,955 shares of the company’s stock, valued at $2,026,545.10. This represents a 17.69% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 13,062 shares of company stock valued at $1,797,634. Insiders own 7.00% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its holdings in TransMedics Group by 0.3% in the third quarter. Vanguard Group Inc. now owns 3,605,607 shares of the company’s stock worth $404,549,000 after acquiring an additional 9,650 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in shares of TransMedics Group by 244.7% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 3,113,082 shares of the company’s stock worth $209,448,000 after purchasing an additional 2,209,996 shares during the last quarter. Geode Capital Management LLC boosted its stake in TransMedics Group by 1.4% in the 2nd quarter. Geode Capital Management LLC now owns 804,650 shares of the company’s stock worth $107,845,000 after purchasing an additional 11,241 shares in the last quarter. Two Sigma Investments LP boosted its stake in TransMedics Group by 54.2% in the 3rd quarter. Two Sigma Investments LP now owns 635,394 shares of the company’s stock worth $71,291,000 after purchasing an additional 223,409 shares in the last quarter. Finally, Marshall Wace LLP grew its position in TransMedics Group by 258.7% during the 2nd quarter. Marshall Wace LLP now owns 546,787 shares of the company’s stock valued at $73,275,000 after purchasing an additional 394,340 shares during the last quarter. Institutional investors own 99.67% of the company’s stock.

About TransMedics Group

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.